



## For use in South and West Hertfordshire and East and North Hertfordshire

#### NICE TECHNOLOGY APPRAISALS – RECOMMENDED NICE TA 217 – DONEPEZIL, GALANTAMINE, RIVASTIGMINE AND MEMANTINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE (REVIEW), MARCH 2011, UPDATED SEPTEMBER 2015, OCTOBER 2018, JULY 2020 AND FEBRUARY 2021

AMBER INITIATION - RECOMMENDED FOR RESTRICTED USE. SPECIALIST INITIATION AND TITRATED TO AN OPTIMAL DOSE AND STABILISED BY SPECIALIST SERVICES. PRIMARY CARE PRESCRIBING UNDER PRESCRIBING SUPPORT DOCUMENT


#### **RECOMMENDATIONS:**

- Patients with all grades of dementia should be referred to a specialist for assessment.
- There has been a statutory duty to commission this TA from 23 June 2011.
- Patients referred to Hertfordshire Partnership University NHS Foundation Trust (HPFT)
  - HPFT are responsible for initiation and stabilisation of dementia treatment. Dose is titrated and patient is monitored and reviewed for 6-8 months by HPFT before asking GP to take over prescribing responsibility.
  - GPs may be requested to undertake the responsibility for the continued prescribing <u>and</u> annual monitoring of dementia treatment in primary care as detailed in the 'Prescribing support document' below.
- Patients referred to other Provider Trusts
  - Prescribing responsibility may be accepted by GPs in the presence of appropriate '**Shared Care/Transfer of Care/Prescribing Support**' guidelines supplied by the Provider.
  - The 'Shared Care/Transfer of Care/Prescribing Support' guidelines supplied:
    - must have been ratified by the Host Commissioner of the Provider Trust.
    - must detail the responsibilities of the different parties sharing care.
    - must contain stopping criteria that have been discussed with the patient and carer(s) at the time of treatment initiation.

NICE Technology Appraisal Guidance 217 is available at: www.nice.org.uk/TA217

This recommendation is based upon the evidence available at the time of publication. The recommendation will be reviewed upon request in the light of new evidence becoming available.

## Prescribing Support Document: Management of Dementia Drugs Process Summary



## Prescribing Support Document: Drugs for the Management of Dementia (donepezil, galantamine, rivastigmine, memantine)

Change History	1	
Version number	Change details	Date
V 1.0	Transfer of Care Guidelines	June 2016
V 2.0	Document updated to Prescribing support document. Transfer of care form removed. This is replaced by a clinic	November 2018
	letter sent by Psychiatrist to the GP.	
	GP fax back reply for refusal of transfer of care – removed.	
<ul> <li>V 3.0</li> <li>Document updated following publication of NICE guideline (NG97) - Dementia: assessment, management and support for people living with dementia and their carers; changes include:</li> <li>potential use of dual pharmacological treatment in patients with moderate or severe Alzheimer's disease;</li> <li>acetylcholinesterase (AChE) inhibitors should not be stopped in people with Alzheimer's disease because of disease severity alone.</li> </ul>		July 2020
	<ul> <li>Additional minor updates made where necessary (e.g. removal of references to Local Incentive Scheme, updated weblinks and drug costs).</li> <li>Additional information added as suggested by ENHCCG mental health prescribing lead/HPFT (to aid clarity).</li> </ul>	
V 4.0		
V 5.0 Harmonisation of Hertfordshire Medicines Management Committee (HMMC) guidance and West Essex Medicines Optimisation Programme Board (WEMOPB) guidance updates include: • Rebadging with HWE ICB and removal of ENHCCG and HVCCG headers		December 2023
	<ul> <li>Removal of reference to CCGs and change HV to SWH</li> </ul>	
V5.1	Updated wording on swallowing difficulties	September 2024

## 1. Introduction

The clinical management of patients with dementia in Hertfordshire, including the prescribing of dementia drugs, has been the responsibility of the Specialist Mental Health Teams for Older People (SMHTOP), Hertfordshire Partnership University NHS Foundation Trust (HPFT) since the implementation of NICE guidance (TA 217) in 2011. The Early Memory Diagnosis and Support Service (EMDASS) is responsible for the diagnosis and initiation of medication.

There is an agreement between both South west Herts place and East and North Herts place and HPFT for appropriate patients who are maintained on a stable dose of dementia medication to be transferred to the General Practitioner (GP) for on-going prescribing and monitoring in primary care.

The aim of this guideline is to ensure that the transfer of care of the patient with dementia from EMDASS to the GP is safe and appropriate by providing the following information: -

- The roles and responsibilities of the secondary care specialist team, the GP, the ICB and patient/carer.
- Criteria for the transfer of prescribing from secondary care to the GP.
- Clinical information on the drugs used in the management of dementia including the monitoring requirements of these medications in primary care.

- Cognitive, global, functional and behavioural assessment scales (where appropriate).
- Criteria for when medication should be stopped.
- When and how to refer back to specialist services.
- Secondary care contact details for support and back-up advice.

The GP will assume both the clinical and legal responsibility of prescribing the dementia drugs and the clinical management of the patient. Patients considered complex by the HPFT Old Age Psychiatrist will be excluded from the transfer of care arrangement.

## 2. NICE guidance

#### NICE TA 217 (Mar 2011) recommends: -

- The three anticholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as options for managing mild to moderate Alzheimer's disease.
- The glutamate receptor antagonist, memantine, alone (monotherapy) as an option for managing Alzheimer's disease for people with:
  - o Moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors
  - Severe Alzheimer's disease

#### (PLEASE SEE BELOW [NG97] REGARDING UPDATED ADVICE ON DUAL PHARMACOLOGICAL THERAPY)

- Patients who continue on treatment should be reviewed regularly using cognitive, global, functional and behavioural assessment. Carer's views on the patient's condition on follow-up should be sought\*.
- AChE inhibitor treatment should normally be started with the drug with the lowest acquisition cost (taking into account required daily dose and the price per dose). However, an alternative AChE inhibitor could be prescribed if considered appropriate taking into account adverse event profile, expectations about adherence, medical comorbidity, possibility of drug interactions and dosing profiles.
- Except as part of properly constructed clinical studies, do <u>not</u> use:
  - o acetylcholinesterase inhibitors or memantine for cognitive decline in vascular dementia
  - o acetylcholinesterase inhibitors in mild cognitive impairment.

#### \*Please see Section 9 (Monitoring Requirements in Primary Care) for further details

**NICE guideline [NG97]** - Dementia: assessment, management and support for people living with dementia and their carers was published in June 2018. This included two changes surrounding pharmacological treatment options as follows:

- For people with an established diagnosis of Alzheimer's disease who are already taking an acetylcholinesterase (AChE) inhibitor:
  - consider memantine in addition to an AChE inhibitor if they have moderate disease
  - offer memantine in addition to an AChE inhibitor if they have severe disease

Following discussion at the Hertfordshire Medicines Management Committee (in June and October 2019), the committee supported dual pharmacological therapy (with AChE inhibitor and memantine) for both moderate and severe Alzheimer's disease (in line with NICE guidance). Dual pharmacological therapy to be initiated only by specialists in the care of patients with dementia (where clinically appropriate).

## 3. Criteria for transfer of prescribing and monitoring to primary care

The following must apply before the GP is asked to accept on-going prescribing responsibility and monitoring of the patient in primary care: -

- The patient must have undergone the appropriate assessments and shown a beneficial response to treatment
- The patient is stable on a maintenance dose of dementia drug
- The patient's care plan is stable\* or predictable

#### The *inclusion* criteria include:

• The patient must have undergone the appropriate assessments and shown an ongoing overall benefit from treatment

- The patient is \*stable on a maintenance dose of dementia drug
- The patient's care plan is stable or predictable
- Alzheimer's Disease
- Dementia in Parkinson's Disease
- Dementia with Lewy Bodies
- Mixed dementia (has to include one of the above types of dementias)

The exclusion criteria include: -

- Vascular dementia
- Fronto-temporal dementia
- Memantine for mild dementia (unlicensed)

\*'Stable' for the purpose of the transfer of care arrangement is defined as when the patient is living at their usual address without requiring any additional psychiatric service other than the memory clinic (EMDASS).

The request for the transfer of care will usually be made when the patient has been on 6-8 months of treatment.

#### 4. Areas of responsibility

ICB	RESPONSIBILITIES		
1	ICB will review the prescribing support document annually.		
SPE	SPECIALIST RESPONSIBILITIES (HPFT Consultant and associated team)		
1	Initial assessment of patient to include tests of cognitive (MMSE or alternative score), global, functional and		
	behavioural symptoms and activities of daily living.		
2	Confirm the diagnosis of dementia. Ensure patient has access to an overall programme of care.		
3	Counsel patients and carers on the implications of the diagnosis, the likelihood of potential benefits and side		
	effects of treatment and treatment endpoints and include the consequence of poor compliance. Provide patient		
	with comprehensive advice and information. HPFT's Choice and Medication website can be used:		
	https://www.choiceandmedication.org/hertfordshire/condition/dementia-and-alzheimers-disease/		
	https://www.choiceandmedication.org/hertfordshire/printable-leaflets/		
Δ	Initiate and stabilise treatment with donenezil galantamine, rivastagmine and/or memantine if clinically		

Initiate and stabilise treatment with donepezil, galantamine, rivastagmine and/or memantine if clinically appropriate, and ensure compliance.

- The preferred option is **generic donepezil standard tablets** for mild to moderate severity Alzheimer's disease. Generic rivastigmine tablets would normally be a 2<sup>nd</sup> line choice if donepezil cannot be tolerated.
- Where there are specific patient reasons where these preferred choices cannot be used, the rationale for the choice of drug/formulation must be communicated to the GP and documented in the patient's notes.
- Memantine monotherapy is an option in moderate Alzheimer's disease for people who are intolerant or have a contraindication to AChE inhibitors, or in severe Alzheimer's disease.
- **Dual pharmacological therapy**: for people with an established diagnosis of Alzheimer's disease who are already taking an acetylcholinesterase (AChE) inhibitor:
  - consider memantine in addition to an AChE inhibitor if they have moderate disease
  - offer memantine in addition to an AChE inhibitor if they have severe disease.

	• HPFT fully supports the use of equivalent cost-effective 'branded generics' in primary care i.e. galantamine XL.
5	Advise GP on any medication or co-morbidity that may worsen cognition and should be reviewed.

- 6 During the first 6-8 months of treatment: -
  - Monitor patient regularly for compliance, side-effects and signs of deterioration. Report adverse events via the yellow card scheme, if appropriate.
- Increase the dose at appropriate intervals or switch to alternative drug/formulation if there are signs of intolerance.

# 7 Assessment of patient for evidence of treatment efficacy at approximately 3 months (2 – 4 months depending on time spent at sub-therapeutic doses during titration). Medication should be continued only where there has been

_			
	an improvement or no deterioration in MMSE (or alternative) score, together with evidence of global improvement		
	on the basis of behavioural and/or functional assessment.		
8	Discontinue treatment where there has not been benefit or where there has been deterioration of the condition.		
9	<ul> <li>If appropriate for patient to continue with medication, GP to be promptly informed to take on further prescribing and monitoring in primary care after 6-8 months. The following information (as a minimum) to be provided to the GP in order that the on-going prescribing and monitoring can be taken on in primary care - see checklist in Section 5 – Communication and Handover from secondary to primary care:-</li> <li>Prescribing support document</li> <li>Clear diagnosis and care plan</li> </ul>		
	<ul> <li>Confirmation that the patient is stable on a maintenance dose and there has been ongoing overall benefit from treatment</li> <li>Eight weeks' prescription of on-going medication from last appointment</li> <li>Specialist team contact details for GPs to obtain advice and support</li> <li>Patient has been fully informed with regards to their treatment and consent has been discussed and documented including the change in where their future prescriptions will be issued from (GP not HPFT). This includes informing patients that their medication (i.e. galantamine XL) may be switched to an equivalent 'branded generic' product by the GP. The 'branded generic' is a preferred ICB choice which is cost-effective in primary care.</li> </ul>		
1	Specialist to ensure that patient/carer is informed and made aware of their responsibilities (as detailed under		
0	patient/carer responsibilities in these guidelines) for when transfer of care to the GP occurs.		
CD	RESPONSIBILITIES		
GP			

1	Review the request from the specialist to take on the transfer of prescribing and monitoring of the patient. Acceptance is assumed.
	Prompt communication to EMDASS if prescribing responsibility is not accepted (within 2 weeks), including the
	clinical reason for not taking on the transfer of care. Responsibility cannot be declined on grounds of cost of
	medication.
2	Check sufficient information has been provided to take on the responsibility of continued prescribing and monitoring – see Section 5 'Communication and handover from secondary to primary care' checklist. Request any missing information to be provided from EMDASS consultant before taking on the prescribing in primary care. Transfer of care can be declined by GP if insufficient detail is received following request for further information.
3	Prescribe donepezil, galantamine, rivastigmine and/or memantine at the maintenance dose recommended. Switch to the ICB preferred cost-effective 'branded generic' product where relevant i.e. galantamine XL.
4	Monitor treatment as stated in Section 9 'Monitoring in Primary Care' in the prescribing support document. Report adverse events via the yellow card scheme, if appropriate.
5	Seek advice from the specialist on any aspect of patient care of concern to the GP that may affect treatment. See
	Section 6 and 7 'Contact details for backup advice and support' in the prescribing support document.
6	Check for possible drug interactions when newly prescribing or stopping concurrent medication.
7	Discontinue treatment if patient develops side-effects, or seek advice if progression of disease is noted, indicating
	need for a review of management plan. AChEIs should not be stopped because of disease severity alone – see
	Section 10 'Stopping Medication' in the prescribing support document.
8	Refer patient back to secondary care when appropriate, clearly highlighting that the referral relates to a patient
	under this transfer scheme – see Section 11 'Triggers for re-referral to secondary care' in the transfer of care
	guidelines.

PA	PATIENT/CARER RESPONSIBILITIES		
1	Report to their GP if they do not have a clear understanding of or have any concerns with their treatment with		
	donepezil, rivastigmine, galantamine or memantine.		
2	Inform their GP of any over the counter products (the GP will know all the other medications that are being		
	prescribed for the patient) and tell the pharmacist of their prescribed medication when buying over the counter		
	medications.		
3	Report any adverse effects to the GP or whilst taking donepezil, galantamine, rivastigmine or memantine.		
4	Report any changes in disease symptoms to the GP.		

## 5. Communication and Handover from Secondary to Primary care

The following information should be provided/action undertaken when requesting the transfer of prescribing of the patient with dementia to primary care

- Clear diagnosis and care plan including information that has been discussed with patient and carer.
- Details of drug treatment and dose.
- Confirmation that the patient is \*stable on a maintenance dose and there has been benefit from treatment.
- Eight weeks prescription of on-going medication from last appointment.
- Specialist team contact details for GPs to obtain advice and support.
- Confirmation that patient has been fully informed with regards to their treatment and consent has been discussed and documented including the change in where their future prescriptions will be issued from (GP not EMDASS).
- The post-diagnostic support service will work in parallel with the secondary care titration clinic. The postdiagnostic support service will provide the following information to the GP (if consent from the patient is obtained):
  - > Confirmation of the standard information handed to the patient.
  - > Details of whether advanced care plan has been agreed or discussed.
  - > Any patient or carer specific information (at discretion of professional).
  - > Any useful telephone numbers.
  - Report at discharge.
  - Specialist team contact details for back-up advice and support.
- Advice on any medication or co-morbidity that may worsen cognition and should be reviewed (if applicable).
- Link to the prescribing support document (to provide additional information for GPs).

## 6. The Principles of Access to Back-Up Advice:

- GPs are expected to use the usual crisis pathway for crisis support (as with other patients).
- The EMDASS/SMHTOP team will respond to GP requests for back-up advice by telephone *within 24 hours* and will provide access to consultant clinics *within 2 weeks* (when needed).
- The GP will be able to contact the post-diagnostic support service (Inc. the dementia carers support nurse) to enable targeted support when patients/carers may be approaching crisis. The GP will be able to refer to the Alzheimer's Society, or other community based organisations (as usual) for signposting and support.

## 7. EARLY MEMORY DIAGNOSIS & SUPPORT SERVICE (EMDASS)

EAST	
Team Manager: Jan Gardiner	Rosanne House
	Parkway
Team Lead: Jennifer Miller	Welwyn Garden City
	Herts AL8 6HG
Doctors:	
Dr Virender Marwah	<b>T:</b> 01707 364 012
Dr Hema Ananth	
Dr Kaushik Mukhopadhaya	E: ENHERTS.SMHTOP@NHS.NET
Dr Sujatha Merve	
NORTH	

Team Manager: Michael Cruz	SMHTOP North
	1st Floor, Saffron Ground
Team Lead: Amanda Lewis	Ditchmore Lane
	Stevenage
Doctors:	Herts
Dr Kunle Ashaye	SG1 3LJ
Dr K Shankar	
	<b>T:</b> 01438 792120
	E: <u>Emdass.north@nhs.net</u>
SOUTH WEST	
Team Manager: Rob Standen	Colne House
	21 Upton Road
Team Lead: Alfred Asimeng	Watford
	Herts WD18 0JP
Doctors:	
Dr Amirtha Pasupathy	<b>T:</b> 01923 837 154
Dr Shaheen Shora	E: <u>hpft.swherts.emdass@nhs.net</u>
NORTH WEST	
Team Manager: Matt Stewart	The Marlowes Health and Wellbeing Centre
	39-41 Marlowes
Team Lead: Robin Firminger	Hemel Hempstead
	Hertfordshire
Doctors:	HP1 1LD
Dr Mike Walker	
Dr Arun Jha	<b>T:</b> 01442275628
Dr Rahul Tomar	E: <u>emdass.nw@nhs.net</u>

## 8. Supporting Information

(For full details, please refer to the current individual drug Summary of Product Characteristics, SmPC, and BNF)

#### Dosage and administration

Treatment should be started at the lowest dose and built up to a tolerable dose within the effective range

#### **Swallowing difficulties**

Please refer to the <u>'specials' alternative guidance</u> for a list of commonly prescribed medicines and alternative methods of administration for patients with swallowing difficulties, feeding tubes or for patients prescribed unlicensed 'specials' medication. Each entry takes into account alternative medicines, formulations, cost and licensing. This list is not exhaustive. As not all medicines are listed, please contact the initiating specialist if required for individual patient advice if a patient has a swallowing difficulty.

Donepezil 5mg once daily in the evening, just before bed, increased if necessary after 1 mon			
	once daily.		
	Orodispersible tablet available (significantly more expensive).		
Rivastigmine Capsule and liquid			
	Starting dose 1.5mg twice daily with meals. Increase dose to maximum tolerated up to 6mg twice		
	daily. Minimum of 2 weeks between dose increases.		
	Patch (only if capsule/liquid cannot be administered)		
	4.6mg/24hours increasing to 9.5mg/24hours after a minimum of 4 weeks. After a further		
	months may be increased to 13.3mg/24 hours if clinically appropriate.		
Galantamine Standard release tablet and liquid			
	Start at 4mg twice daily preferably with meals. Increase to maximum tolerated up to 12mg twice		
	daily. Minimum of 4 weeks between dose increases.		
	Modified release tablet		
	8mg once daily increasing to maximum tolerated up to 24mg once daily. Minimum of 4		
	between dose increases.		
Memantine	Tablet/orodispersible tablet and oral solution		

5mg once daily, increased in steps of 5mg at weekly intervals, until reaching the recommended
maintenance dose of 20mg once daily.
Orodispersible tablets and oral solution available (significantly more expensive); orodispersible
tablets used in preference to oral solution at HPFT.
Oral solution should be dosed onto a spoon or into a glass of water.

Absolute Contraind	lications		
All drugs	Where there is hypersensitivity to the active substance or any of the excipients.		
Donepezil	Known sensitivity to piperidine derivatives		
Galantamine	Severe hepatic/renal impairment or those who have both significant renal and hepatic		
	dysfunction. Urinary retention or history of prostatic condition		
Donepezil &	Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency		
galantamine	or glucose-galactose malabsorption		
Rivastigmine	Known hypersensitivity to carbamate derivatives or severe liver impairment		
Memantine	Patients with rare hereditary problems of fructose intolerance should not take oral solution		
	(contains sorbitol).		
Cautions – to be us	ed with caution in the following		
AChE inhibitors (donepezil, galantamine, rivastigmine)	<ul> <li>Sino-atrial, AV node block or sick sinus syndrome</li> <li>Severe asthma</li> <li>Concomitant beta-blocker therapy</li> <li>Urinary symptoms (avoid use of galantamine)</li> <li>People at increased risk of peptic ulcers (those with history of ulcer disease or on concomitant NSAIDs</li> <li>Chronic obstructive pulmonary disease or active pulmonary infections</li> <li>Epilepsy</li> <li>CVD</li> </ul>		
Memantine	<ul> <li>History of convulsions</li> <li>Patients with recent MI, uncontrolled hypertension or uncompensated congestive heart failure were excluded from the clinical trials and there is limited data for the use in these patients. These patients should be closely supervised.</li> <li>Patients who have had drastic diet changes e.g. carnivore to vegetarian or a massive ingestion of alkalising gastric buffers since this causes alkalisation of urine which reduces elimination of memantine.</li> </ul>		

Adverse effects of AChE inhibitors (donepezil, galantamine, rivastigmine) and suggested actions

There are two practically important groups of adverse effects:

- 1. GI common S/Es include abdominal pain, nausea, vomiting, diarrhoea, anorexia, weight loss
- 2. Cardiac
  - heart block (sino-atrial block, AV block) this is rare but potentially serious and easily missed
  - bradycardia if this occurs, carry out an ECG. If symptoms of collapse or dizzy spells and PR interval >200ms, then stop AChE inhibitor

Adverse effects	Symptoms/signs	Frequency	Suggested actions
GI symptoms	Anorexia, nausea, vomiting and diarrhoea	Very common	Generally mild and transient. Can be minimised by taking drug after food. If symptoms persist, reduce dose. If unsuccessful, consider switch to alternative AChE inhibitor.
	May enhance predisposition to gastric or duodenal ulceration	Uncommon/rare	Discontinue treatment if ulcer develops. Care with those at risk of or with active gastric or duodenal ulcer. Patient should be monitored regularly for symptoms.

Cardiovascular symptoms	Bradycardia	Uncommon/rare	Seek urgent review. Carry out an ECG. If symptoms of collapse or dizzy spells and PR interval >200ms then stop AChE inhibitor.
Neurological symptoms	Dizziness, headache, insomnia, somnolence	Very common / common	Generally mild and transient. If symptoms persist, reduce dose. If unsuccessful, consider switch to alternative AChE inhibitor/memantine.
	Syncope	Common/ uncommon	Reduce dose. If symptoms persist, consider switch to alternative AChE inhibitor/memantine.
	Extrapyramidal symptoms (including worsening of Parkinson's disease)	Rare	Reduce dose. If symptoms persist, consider switch to alternative AChE inhibitor/memantine.
	Decreased seizure threshold	Rare	Extreme caution in epilepsy
Skin	Galantamine has been associated with <b>serious skin</b> <b>reactions</b> including Stevens Johnson Syndrome (SJS), acute generalised exanthematous pustulosis (AGEP) and erythema multiforme.	Rare	It is recommended that patients and carers are advised to <b>monitor</b> for skin reactions. In the advent of an apparent skin reaction patients should be advised to <b>stop treatment</b> <b>and seek medical advice</b>
General disorders	Asthenia, fatigue	Common	Generally mild and transient. If symptoms persist, reduce dose. If unsuccessful, consider switch to alternative AChE inhibitor/memantine.
Respiratory symptoms	May cause bronchoconstriction	No data available	Caution in patients with history of asthma or COPD or those with an active pulmonary infection (pneumonia).
Psychiatric symptoms	Agitation, confusion and insomnia	Common	Reduce dose. If symptoms persist, consider switch to alternative AChE inhibitor/memantine.
Adverse effects	of memantine and suggested a	ictions	
Appears to be v		is important to not	e that it might be easy to miss distressing side ntia.
Adverse effects	Symptoms/signs	Frequency	Suggested actions
		_	

Auverse	Symptoms/signs	Frequency	Suggested actions
effects			
GI symptoms	Constipation	Common	PRN or regular laxative
Cardiovascular	Hypertension	Common	Reduce dose and review BP. Consider
symptoms			discontinuation
Neurological	Dizziness, headache,	Common	Reduce dose and review symptoms. Consider
symptoms	drowsiness		discontinuation
Respiratory	Dyspnoea	Common	Reduce dose and review symptoms. Consider
symptoms			discontinuation

Drug Interactio	ons
All AChE inhibitors	<ul> <li>May interact (antagonism of effects) with medicines that have anticholinergic activity e.g. oxybutynin, antipsychotics and tricyclics.</li> <li>Potential for synergistic activity with medicines such as succinylcholine (suxamethonium) and other neuromuscular blocking agents, cholinergic agonists or beta-blocking agents that have effects on cardiac conduction.</li> <li>Potential for additive effects with other drugs that share the same side effects e.g. beta blockers and bradycardia, SSRIs and anorexia)</li> </ul>

Donepezil and	Metabolised via CYP3A4 and CYP2D6 pathways in the liver. Inhibitors of these pathways (e.g.
galantamine	erythromycin, clarithromycin, ketoconazole, fluvoxamine, fluoxetine, paroxetine) may increase
	drug levels and patients may experience increased side effects. A dose reduction may be required.
	Enzyme inducers (e.g. rifampicin, phenytoin, carbamazepine and alcohol) may reduce levels so care
	should be taken with concurrent prescribing.

#### Costs (Source: Drug Tariff and Dictionary of Drugs & Medical Devices June 2020)

All costs below are quoted for maximum doses. Treatment is often at maximum dose although practice varies. In the case of oral rivastigmine, the maximum is often not reached.

Drug	Formulation	Dose	28 days cost	Annual Cost
Donepezil	Tablets	10mg od	£1.36	£18
	Orodispersible tablets	10mg od	£10.43	£136
Rivastigmine	capsules	6mg bd	£33.00	£430
	Oral solution 2mg/ml (120ml bottle)	6mg bd (6ml)	£193.64 (120ml = £96.82)	£2524
	Patches	13.3/24	£77.97	£1016
		9.5/24	£19.97	£260
		4.6/24	£77.97	£1016
Galantamine	Standard release tablets	8mg bd	£63.29	£825
		12mg bd	£77.27	£1007
	Modified release capsules	16mg od	£64.90	£846
	(prescribed generically)	24mg od	£79.80	£1040
	Modified release capsules	16mg od	£32.45	£423
	(branded generic Gatalin XL®)	24mg od	£39.90	£520
	Oral solution 4mg/ml	8mg bd (4ml)	£240 (100ml = £120)	£1800
	(100ml bottle)	12mg bd (6ml)	£240	£2640
Memantine	Tablets	20mg od	£10.48	£136
	Orodispersible tablets	20mg od	£49.98	£652
	Oral solution 10mg/ml	20mg od	£61.77 (50ml = £55.15)	£741

## 9. Monitoring requirements in primary care.

Monitor for adverse effects and drug interactions (see section 8 for details and suggested actions). The most relevant are:

- Exacerbation of asthma and COPD
- Anorexia and weight loss
- GI ulcer or bleed
- AV node block as a possible cause of collapse
- Potential additive effects with other drugs that share the same side effects (e.g. beta-blockers and bradycardia; SSRIs and anorexia)

#### Annual Monitoring Review in Primary Care

The following is a summary of the components to be included in the annual monitoring review of the patient:-

1. Compliance - is	1. Compliance - is the medication being taken properly?		
2. Physical Healt	2. Physical Health Monitoring		
Weight	If weight loss has started or accelerated after starting AChE inhibitor medication, this may be the cause		
Pulse	If <60, carry out an ECG. If PR interval > 200ms, stop drug or discuss with mental health specialist		
U+Es and LFTs	Renal or hepatic impairment may reduce an individual's tolerability to rivastigmine and/or donepezil		
Overall tolerance	GI symptoms - anorexia, nausea, vomiting and diarrhoea		
to medication	Neurological symptoms – headaches, dizziness, drowsiness, syncope		
	See section 8 for full details and suggested actions		

#### 3. Impact on global functioning

Functional and behavioural assessment is best made via a discussion with the patient and carer (it might be important to see the carer alone to elicit behavioural problems). [Rating scales do exist for functional, behavioural and global assessment but most were designed for research purposes and none has become widely established for practical clinical use. See Appendix 1 for available assessment scales.]

Functional	Impact on daily living. Is there declining	Review whether referral to Social Services
assessment	function?	(HCS) is required for declining function
Carer Impact	Does the carer value the effect of the medication?	It is important to take into account the impact of the medication to the carer
Behavioural assessment	New behavioural problems? Is the patient displaying behavioural and psychological symptoms of dementia (BPSD)?	Review whether standard or urgent referral to SMHTOP via SPA is needed for new behavioural problems

#### 4. Cognitive Assessment

• Some patients are distressed by repeated use of formal cognitive scoring tests. Therefore, it is not always necessary to repeatedly use a formal scale to measure cognition as this can also be assessed via patient and carer interview. Use of formal cognitive scales is not mandatory.

- It is also important to consider the global functioning of the patient by discussion with the carer/relatives. It is often the case that no management change is likely whatever the result of the test (i.e. the global functional, behavioural and global assessments are positive and the dementia is not severe).
- However, in some cases a formal test can help find severe dementia and highlight that ongoing benefit of treatment is unlikely. An unexpectedly large change in a test score might prompt a conversation about other problems that need management e.g. increased care package.
- When the use of a formal cognitive scoring test is appropriate (e.g. when there has been a significant deterioration in the global functioning), consider using either of the following open access primary care validated scales 6CIT (six item cognitive impairment test) or GPCOG (the General Practitioner assessment of Cognition).
  - See Appendix 1
- 5. Is the medication still of overall benefit?

## **10. Stopping Medication**

AChEls should not be stopped because of disease severity alone in people with Alzheimer's disease. For GP management it is anticipated that if there is still an *overall* benefit and providing the patient is tolerating the treatment and there are no contraindications, the treatment will be maintained until such a time as it becomes inappropriate such as in extreme frailty or a severely impaired stage of dementia (e.g. swallowing difficulties).

Treatment should be stopped if the patient cannot tolerate side effects (see section 8 – adverse effects).

It is advisable to give reducing doses – e.g. donepezil 5 mg od for a month if the patient has been taking 10mg. Similar gradual reduction with other drugs may be used. Research evidence suggests there might not be a withdrawal reaction

from AChEI medication (AD 2000 trial) but anecdotally these have been reported and therefore appears to be a reasonable precaution.

## **11.** Triggers to consult with/refer to secondary care

- Difference of opinion between primary care team and carer about stopping medication
- Consideration of use of dual pharmacology therapy in patients with moderate or severe Alzheimer's disease, and a global impression that cognitive enhancement would be of benefit for the service user
- Uncertainty about side effects
- Behavioural problems that would require the community team whether or not the patient is taking antidementia medication.

#### Appendix 1 References and Assessment Scales

- NICE TA 217 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE March 2011
- NICE Dementia: assessment, management and support for people living with dementia and their carers (NG97). NICE June 2018: <u>https://www.nice.org.uk/guidance/ng97</u>
- Mini-mental state examination (Folstein and Folstein 1974) the publishers do not allow free use for health professionals
- 6CIT This is free to use for health professionals and easy to find online (Brooke P, Bullock R; Validation of a 6 item cognitive impairment test with a view to primary care usage. Int J Geriatr Psychiatry. 1999 Nov; 14(11):936-40) <a href="http://www.patient.co.uk/doctor/six-item-cognitive-impairment-test-6cit">http://www.patient.co.uk/doctor/six-item-cognitive-impairment-test-6cit</a>
- **GPCOG** This is free to use for health professionals and easy to find online (Brodaty et al, JAGS 2002; 50:530-534) <u>http://www.patient.co.uk/doctor/general-practitioner-assessment-of-cognition-gpcog-score</u>
- Abbreviated Mental Test Score (AMTS) This is quick and popular in general hospitals. It is not validated in primary care, though compares well against MMSE in some research. (Hodgkinson HM (1972) Evaluation of a mental test score for assessment of mental impairment in the elderly. Age and Ageing 1, 233-8)
   <a href="http://www.patient.co.uk/doctor/abbreviated-mental-test-amt">http://www.patient.co.uk/doctor/abbreviated-mental-test-amt</a>
- Functional Activities Questionnaire (FAQ) in Older Adults with Dementia This measures instrumental activities
  of daily living (IADLs), such as preparing balanced meals and managing personal finances. Since functional changes
  are noted earlier in the dementia process with IADLs that require a higher cognitive ability compared to basic
  activities of daily living (ADLs), this tool is useful to monitor these functional changes over time. The FAQ may be
  used to differentiate those with mild cognitive impairment and mild Alzheimer's disease.
  https://www.alz.org/careplanning/downloads/functional-activities-questionnaire.pdf
- Assessment of Motor and Process Skills (AMPS): a standardised observation-based evaluation of a person's quality of performance of relevant and chosen personal or domestic activities of daily living.
- Model of Human Occupation Screening Tool (MoHOST): The MOHOST addresses client's motivation for occupation, pattern of occupation, communication/interaction, process, and motor skills, and environment. The MOHOST was designed to be used to document progress towards occupational therapy intervention goals as well as to screen for occupational therapy services.

- **Pool Activity Level (PAL)** © **2015 Jackie Pool Associates:** The PAL Instrument contains a valid and reliable tool for assessing level of ability which is recommended in the National Clinical Practice Guideline for Dementia (NICE, 2006), for activities of daily living and for leisure activity. The instrument also contains profiling tools for interpreting the assessment in order to plan and deliver effective, enabling care and support.
- Just checking (<u>http://www.justchecking.co.uk/</u>) an activity monitoring system which can be used to establish routines and patterns of movement within the home. The information gained from this assessment can help inform decision making about future interventions and/or support needed, provide reassurance or as a baseline to compare against in the future if behaviours change.
- Medichec Tool (South London and Maudsley NHS Foundation Trust): a tool to assess anticholinergic burden, as medications with anticholinergic effects are known to increase the risk of cognitive impairment and dementia. Can be used to help clinicians identify which drugs have a cholinergic effect on cognition and defines the extent of this effect. <u>https://medichec.com/</u>

Version	5.1 Updated with wording on swallowing difficulties September 2024.
Developed by	ENH & SWH PMOT
Approved by	HMMC
Date approved/updated	June 2016 updated Feb 2021
Review date:	The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.
Superseded version	<ul> <li>4.0</li> <li>5.0 Harmonisation of Hertfordshire Medicines Management Committee (HMMC) guidance and West Essex Medicines Optimisation Programme Board (WEMOPB) guidance updates include: <ul> <li>Rebadging with HWE ICB and removal of ENHCCG and HVCCG headers</li> </ul> </li> <li>Review date removed and replaced with standard statement</li> </ul>